InvestorsHub Logo
Followers 7
Posts 561
Boards Moderated 0
Alias Born 04/09/2018

Re: zino post# 2440

Sunday, 06/03/2018 2:55:33 PM

Sunday, June 03, 2018 2:55:33 PM

Post# of 3353
Agreed. I don't know how a company offering a treatment for ALS showing positive results and potential to treat MS, Parkinson and Alzheimers doesn't have a $1 billion market cap by now, $50/share as starters. Eventually a $6 billion+ company- $300 PPS. IMO. Look at DYAX buyout by Shire for $6 billion and they were treating hereditary angioedema – a rare blood disorder. Isn't ALS, MS and Parkinsons much more prevalent than hereditary angioedema?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BCLI News